Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis.

Gu-Choul ShinHyeong Min LeeNayeon KimJihyeon HurSang-Ku YooYun Sun ParkHyung Soon ParkDongryeol RyuMin-Ho ParkJung Hee ParkSang-Uk SeoLeo Sungwong ChoiMartin Rønn MadsenMichael FeighKwang Pyo KimKyun-Hwan Kim

Published in: British journal of pharmacology (2024)

Our data demonstrated that VUTI is a promising therapeutic for NASH. Targeting PON2 may be important for improving liver function in various immune-metabolic diseases including NASH.

Keyphrases

cell death
electronic health record
endoplasmic reticulum stress
liver injury
signaling pathway
oxidative stress
cancer therapy
big data
drug induced
data analysis
liver fibrosis
drug delivery
deep learning